Lundbeck Completes DEEp SEA Randomization; Phase III Bexicaserin Trial In Dravet Syndrome Advances

H. Lundbeck announced that the final patient has been randomized in DEEp SEA, a global Phase III trial of investigational bexicaserin for children and adults with Dravet syndrome. Completion of enrollment advances the program toward potential pivotal efficacy and safety readouts, but no clinical data or regulatory timeline was disclosed.